Omar Tirmizi, MD
Pulmonary Disease · Culver City, CANPI 1306902739
Payments from drug & device makers
Across 225 payments — averaging $55.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$5K
- AstraZeneca$4K
- GSK$1K
- Jazz Pharmaceuticals Inc.$318
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$297
- Mylan Specialty L.p.$295
- plus $2K from 29 others
What the payments were for
- Speaking & faculty fees$7,04056%
- Food & beverage$5,31543%
- Education$1331%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 34 | $4,852 |
| AstraZeneca(2 entities) | 26 | $3,898 |
| GSK | 54 | $1,099 |
| Jazz Pharmaceuticals Inc. | 13 | $318 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $297 |
| Mylan Specialty L.p. | 15 | $295 |
| Pulmonx Corporation | 3 | $242 |
| Pfizer | 10 | $212 |
| Sanofi | 7 | $150 |
| Advanced Respiratory, Inc | 5 | $140 |
| Novartis | 5 | $109 |
| Grifols USA, LLC | 3 | $74 |
| Insmed, Inc. | 3 | $70 |
| Electromed, Inc. | 7 | $67 |
| Genentech USA, Inc. | 4 | $63 |
| Merck | 3 | $55 |
| Sunovion Pharmaceuticals Inc. | 3 | $51 |
| United Therapeutics Corporation | 2 | $46 |
| Baxter Healthcare | 2 | $43 |
| Sanofi-aventis U.S. LLC | 2 | $39 |
| CSL Behring | 2 | $39 |
| Philips North America LLC | 2 | $37 |
| Lilly USA, LLC | 2 | $33 |
| Inspire Medical Systems, Inc. | 1 | $31 |
| Vertiflex, Inc. | 2 | $30 |
| Viatris Specialty LLC | 1 | $28 |
| Inogen, Inc. | 1 | $26 |
| Bayer | 1 | $25 |
| E.r. Squibb & Sons, L.L.C. | 1 | $24 |
| Novo Nordisk | 1 | $24 |
| Johnson & Johnson | 1 | $23 |
| Itamar Medical Inc | 1 | $14 |
| Gilead | 1 | $14 |
| Paratek Pharmaceuticals, Inc. | 1 | $12 |
| Endo Pharmaceuticals Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$3,934
- BREZTRI$2,561
- BREZTRI AEROSPHERE$900
- CHARTIS CATHETER$114
- ZEPHYR DELIVERY CATHETER$114
- ZEPHYR ENDOBRONCHIAL VALVE$114
- PULMONX CHARTIS TABLET CONSOLE$114
How this compares
$12,488 in reported general payments places this provider in the 80th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 123 | $80,005 |
| Dupixent PenDupilumab | 12 | $43,374 |
| JardianceEmpagliflozin | 36 | $43,129 |
| JanuviaSitagliptin Phosphate | 36 | $40,499 |
| EliquisApixaban | 51 | $39,415 |
| EntrestoSacubitril/Valsartan | 23 | $24,471 |
| OzempicSemaglutide | 25 | $22,828 |
| BrilintaTicagrelor | 37 | $22,035 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 39 | $17,302 |
| BelbucaBuprenorphine Hcl | 13 | $13,794 |
| Spiriva HandihalerTiotropium Bromide | 16 | $8,919 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 136 | $4,325 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $3,826 |
| Advair DiskusFluticasone Propion/Salmeterol | 14 | $2,950 |
| Wixela InhubFluticasone Propion/Salmeterol | 21 | $2,084 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta | $1,099 | $97,307162 claims |
| Boehringer IngelheimJardiance | $4,852 | $43,12936 claims |
| MerckJanuvia | $55 | $40,49936 claims |
| PfizerEliquis | $212 | $39,41551 claims |
| AstraZenecaBrilinta, Symbicort | $3,898 | $25,86148 claims |
| NovartisEntresto | $109 | $24,47123 claims |
| Novo NordiskOzempic | $24 | $22,82825 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Culver City
- Toby MaherLos Angeles$27.6M
- David PhamWestminster$5.9M
- Andrew WachtelLos Angeles$5.9M
- Aaron WeinbergIrvine$5.1M
- Michael RothLos Angeles$4.5M
- Namita SoodSacramento$3.7M
- Edward FedermanSan Diego$3.6M
- Sanjay VadgamaSherman Oaks$3.3M
- Rajan SaggarLos Angeles$3.3M
- Samuel LouieSacramento$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.